A case of infliximab-induced lupus in a patient with ankylosing spondylitis: Is it safe switch to another anti-TNF-α agent?

Clinical Rheumatology

Volumn 32, Issue 12, 2013, Pages 1819-1822

  Santiago, Tânia ^a   Santiago, Mariana Galante ^a   Rovisco, João ^a   Duarte, Cátia ^a   Malcata, Armando ^a   Da Silva, José António Pereira ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Ankylosing spondylitis; Anti TNF ; Anti TNF induced lupus; Drug induced lupus; Infliximab

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DIURETIC AGENT; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ABNORMAL RESPIRATORY SOUND; AGED; ANKYLOSING SPONDYLITIS; ANTIBODY TITER; ARTERIAL OXYGEN SATURATION; ARTHRITIS; CARDIOMEGALY; CASE REPORT; CROHN DISEASE; DRUG FEVER; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUPUS LIKE SYNDROME; MALAISE; OXYGEN THERAPY; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN DEFECT; THORAX PAIN; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; METHOTREXATE; METHYLPREDNISOLONE; RECEPTORS, TUMOR NECROSIS FACTOR; RISK; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890428343     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2361-9     Document Type: Review

References (13)

1. Williams EL, Gadola S, Edwards CJ (2009) Anti-TNF-induced lupus. Rheumatology (Oxford) 48:716-720
2. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F (2005) The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 14:931-937
3. De Bandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O (2003) Anti-TNF alpha-induced systemic lupus erythematosus. Clin Rheumatol 22:56-61
4. Ramos-Casals M, Alvarez R-P, Diaz-Lagares C, Cuadrado M-J, Khamashta MA, BIOGEAS Study Group (2010) Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 9:188-193
5. Perez-Garcia C et al (2006) Drug-induced systemic lupus erythematous in ankylosing spondylitis associated in infliximab. Rheumatology 45:114-116
6. Akgül O, KIlIç G, KIlIç E, Cüce I, Ozgöçmen SA (2012) Patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept. Rheumatol Int. doi: 10.1007/s00296-012-2617-8
7. Bodur H, Eser F, Konca S, Arikan S (2009) Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis. Rheumatol Int 29:451-454
8. Mounach A, Ghazi M, Nouijai A, Ghozlani I, Achemlal L, Bezza A, El Maghraoui A (2008) Drug-induced lupus-like syndrome in ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 26:1116-1118
9. Williams VL, Cohen PR (2011) TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 50:619-625
10. Ye C, Sholter D, Martin L, Keeling S (2011) Successful switch of patients with rheumatoid arthritis developing anti-tumor necrosis factor (anti-TNF)-induced lupus to another anti-TNF agent. J Rheumatol 38:1216
11. Wetter DA, Davis MD (2009) Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 84:979-984
12. Cush JJ (2004) Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin Exp Rheumatol 22:S141-S147
13. Kocharla L, Mongey AB (2009) Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another? Lupus 18:169-7